Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EIK1004-001 (IMP1707-001), EIK1004-001
EIK1004 · 1 trial · 1 indication
A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). The number of participants who experience a DLT will be reported.
Number of participants reporting adverse events or serious adverse events which include any abnormal clinical events, laboratory assessments outside of normal clinical range, abnormal vital signs observed, and any abnormal ECG parameters
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | EIK1004 (IMP1707) monotherapy; oral tablet(s) daily (except for the single-dose period). Participants will receive escalating doses of EIK1004 (IMP1707) until progressive disease or discontinuation. |
| Name | Type | Description |
|---|---|---|
| EIK1004-001 (IMP1707-001) | DRUG | PARP1 selective inhibitor |
• Breast cancer: must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+, HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemothe...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
EIK1004 is an investigational small molecule developed by Eikon Therapeutics, Inc. (ticker EIKN) for the treatment of advanced solid tumors. It is a PARP1 selective inhibitor and is currently in Phase 1 clinical development. EIK1004 has not been approved by the FDA and remains under study in a single active trial.
EIK1004 is being studied for the treatment of advanced solid tumors. It is an investigational therapy in Phase 1 development and has not been approved for any indication. The ongoing trial enrolls adults 18 years and older with advanced solid tumors across the United States, Australia, and China.
EIK1004 targets PARP1, poly (ADP-ribose) polymerase 1. It is designed as a PARP1 selective inhibitor, a small molecule modality. The Phase 1 study is biomarker selected, meaning enrollment is guided by biomarker criteria. PARP1 is an enzyme involved in DNA repair processes in cells.
Eikon Therapeutics, Inc. is developing EIK1004. The company trades under the ticker EIKN. Eikon Therapeutics is the sponsor of the Phase 1 clinical program evaluating EIK1004 in advanced solid tumors.
EIK1004 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program consists of one active, recruiting trial with a planned enrollment of 130 participants. No trials for EIK1004 have been completed.
EIK1004 is being evaluated in the Phase 1 trial NCT06907043, titled A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. The trial is currently recruiting, is uncontrolled, and plans to enroll 130 participants across the United States, Australia, and China.
Yes, EIK1004 is also known as EIK1004-001 and IMP1707-001. These alternative names refer to the same investigational PARP1 selective inhibitor developed by Eikon Therapeutics, Inc. for advanced solid tumors. The Phase 1 trial listing also references the compound as IMP1707.